Stay updated on Nivolumab+Ipilimumab+Radiation in MSS/MSI-High CRC/Pancreatic Clinical Trial
Sign up to get notified when there's something new on the Nivolumab+Ipilimumab+Radiation in MSS/MSI-High CRC/Pancreatic Clinical Trial page.

Latest updates to the Nivolumab+Ipilimumab+Radiation in MSS/MSI-High CRC/Pancreatic Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page update only shows a new revision number, changing from v3.4.1 to v3.4.2, with no observable changes to study details or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check18 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 as part of a minor site maintenance; no changes to study data or page content are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check32 days agoChange DetectedUI changes include a glossary toggle (Show glossary / Hide glossary), a capitalization update for the QC label 'Last Update Submitted that Met QC Criteria', and a capitalization update for the No FEAR Act notice to 'No FEAR Act Data', along with a footer revision from v3.3.4 to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check39 days agoChange DetectedRevision: v3.3.4 updated from v3.3.3; no visible changes to the study page content or layout.SummaryDifference0.1%

- Check68 days agoChange DetectedAdded a new 'Locations' section with Washington listed as a site, and removed the old 'Washington Locations' header and the 'HHS Vulnerability Disclosure' footer.SummaryDifference0.2%

- Check90 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Nivolumab+Ipilimumab+Radiation in MSS/MSI-High CRC/Pancreatic Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab+Ipilimumab+Radiation in MSS/MSI-High CRC/Pancreatic Clinical Trial page.